H2RA administration in critically ill patients with acute myocardial infarction was associated with a 32% increased risk of 30-day mortality (HR 1.32) compared to non-H2RA users.
Cohort (n=4,252)
No
Does Histamine H2 Receptor Antagonist (H2RAs) administration increase 30-day mortality in critically ill adult patients with acute myocardial infarction?
In critically ill patients with acute myocardial infarction, administration of H2 receptor antagonists is associated with a significantly increased risk of 30-day mortality.
Effect estimate: HR 1.32 (95% CI 1.09-1.60)
Absolute Event Rate: 11.6% vs 15.2%
p-value: p=0.005
Histamine H2 Receptor Antagonist (H2RAs) administration reduces mortality in critically ill patients with HF, but the association between H2RAs exposure and acute myocardial infarction (AMI) remains unclear. This study aims to investigate the relationship between H2RAs administration and 30-day mortality in critically ill patients with AMI using the MIMIC-IV 3.0 database. A retrospective cohort study was conducted using data from the MIMIC-IV 3.0 database. This study enrolled adult AMI patients and set the primary endpoint as the mortality within 30 days following hospital admission. Multivariable Cox proportional hazards models were employed to adjust for potential confounding factors, including demographic variables, comorbid conditions, and illness severity. Our analysis comprised 4252 patients with AMI, among whom 1557 received H2RAs. The overall 30-day mortality rate observed in the cohort was 13.9%. Following adjustment for confounding factors, H2RAs administration was associated with an increased hazard ratio of 1.32 (95% confidence interval: 1.09-1.6). Further subgroup analyses and propensity score assessments have validated the reliability and consistency of these results. This study revealed a significant association between H2RA administration and an increased 30-day mortality rate in myocardial infarction patients. Our findings highlight the need for further investigation to understand the underlying mechanisms and assess the clinical implications of H2RA use in this susceptible patient population.
Guan et al. (Fri,) conducted a cohort in Acute myocardial infarction (n=4,252). Histamine H2 Receptor Antagonists (H2RAs) vs. Non-H2RA users was evaluated on 30-day mortality (HR 1.32, 95% CI 1.09-1.60, p=0.005). H2RA administration in critically ill patients with acute myocardial infarction was associated with a 32% increased risk of 30-day mortality (HR 1.32) compared to non-H2RA users.